Article Text

Download PDFPDF
Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study
  1. Elisa Tripodi1,
  2. Gennaro Cormio2,3,
  3. Ugo De Giorgi4,
  4. Giorgio Valabrega5,
  5. Daniela Rubino6,
  6. Stefano Lepori1,
  7. Giuseppa Maltese1,
  8. Ilaria Sabatucci1 and
  9. Domenica Lorusso1
  1. 1 Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  2. 2 Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
  3. 3 Gynecologic Oncology Unit, University of Bari, Bari, Italy
  4. 4 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
  5. 5 Candiolo Cancer Institute FPO - Oncology, Candiolo, Italy
  6. 6 SSD Oncologia Medica Istituto "F.Addarii", Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
  1. Correspondence to Domenica Lorusso, Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy; kettalorusso{at}libero.it

Abstract

Background Pegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long survivor patients with recurrent ovarian cancer, as evaluated for platinum agent, paclitaxel and gemcitabine. The aim of the present study was to evaluate the anti-tumor activity and the toxicity profile of re-challenge of PLD in recurrent ovarian cancer patients.

Methods Data on 27 patients with epithelial ovarian cancer treated in the last ten years (2007-2017) with palliative PLD rechallenge were included in this multicenter retrospective Italian study.

Results The objective response rate to PLD re-treatment were complete response in 19%, partial response in 30% and stable disease in 37%. Only 1 case of G4 hematological toxicity was reported. No patient experienced severe cardiac impairment (G2-4).

Conclusion PLD rechallenge represents an active and safe possibility of treatment for long survivor ovarian cancer patients.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Provenance and peer review Not commissioned, externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.